Hepatic progenitor cells, senescence and IL-6 as the main players in combined hepatocellular-cholangiocarcinoma development
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Blocking IL-6 trans-signaling using soluble gp130, clearing senescent cells using a senolytic agent, or depleting hepatic progenitor cells results in significant reduction of hepatocellular-cholangiocarcinoma tumors.
“Blocking IL-6 trans-signaling using soluble gp130 or clearing senescent cells using a senolytic agent, as well as the depletion of hepatic progenitor cells, result in a significant reduction of hepatocellular-cholangiocarcinoma tumors [44, 45].”
From The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases (2024) · cites this paper as [45]
Cited by
Sorted by citations
The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases
Wang, M.-J., Zhang, H.-L., Chen, F., Guo, X.-J., Liu, Q.-G., & Hou, J. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00527-1 · Cited by 84 · see citing works
“Blocking IL-6 trans -signaling using soluble gp130 or clearing senescent cells using a senolytic agent, as well as the depletion of hepatic progenitor cells, result in a significant reduction of hepatocellular-cholangiocarci-noma tumors [44, 45].”
Background
- Authors
- Arechederra, M., & Fernández-Barrena, M. G.
- Affiliations
- Instituto de Salud Carlos III (ES)
- ORCID
- Arechederra, María
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 77
- Issue
- 6
- Pages
- 1479-1481
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4296628011
- Cited by
- 9
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gobierno de Navarra Departamento de Salud (2018-055)
- Gobierno de Navarra
- Fundación Científica Asociación Española Contra el Cáncer (POSTD18014AREC)
- Federación Española de Enfermedades Raras
- Instituto de Salud Carlos III (PI19/00613)
- Gobierno de España Ministerio de Ciencia e Innovación (PID2020-117116RB-I00, RYC2018-024475-1)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- combined hepatocellular-cholangiocarcinoma, hepatocellular carcinoma, cholangiocarcinoma, hepatic progenitor cells, cellular senescence, interleukin-6, liver cancer, hepatoblastoma
- MeSH terms
- Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Stem Cells, Interleukin-6, Cholangiocarcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
